Elixiron Immunotherapeutics
↗Taipei, Taiwan
Elixiron Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing precision immunotherapies for neurodegeneration, autoimmune diseases, and oncology. Founded in 2017, the company utilizes a pathway-centric approach, integrating translational medicine, multi-omics, and AI-driven analytics to identify targets and develop novel therapies.
The company's pipeline includes small molecule inhibitors, monoclonal antibodies, and mRNA technologies. Elixiron has gained recognition for its innovative research, receiving awards such as the Taiwan BIO Award and the National Innovation Award, and has secured non-dilutive funding from the Alzheimer's Association and Bill Gates' 'Part the Cloud' initiative.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology, Neurodegeneration, Autoimmune
SIZE & FINANCIALS
Employees:51-200
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$31M
Investors:Pangu Capital, Taiwania Capital, DCI Partners (Daiwa Securities Group), Mega International Commercial Bank, Fubon Financial Holdings, Hong Tai Electric Industrial, China Development Capital Industrial Bank Capital Group
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, mAb, mRNA
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Alzheimer's Association (Grant/Funding), 4B Technologies Ltd. (Licensing), Pilatus Biosciences Inc. (Licensing)
COMPETITION
Position:Emerging
Competitors:Daiichi Sankyo, Janssen
LEADERSHIP
Key Executives:
Hung-Kai (Kevin) Chen - Chairman and CEO
Carrie Duan - Executive Vice President of Clinical Development
Pandelakis Koni - Executive Vice President of R&D
Scientific Founders:Hung-Kai Chen, Zhenglun Gu, Muhua Yang
LINKS
Website:elixiron.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Elixiron Immunotherapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Elixiron Immunotherapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.